Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Profound Medical ( (TSE:PRN) ) has issued an announcement.
Profound Medical Corp. is set to release its fourth quarter and full year 2024 financial results on March 6, 2025. The announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic developments. The results will be discussed further in a conference call, offering a platform for management to outline business progress and future directions.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue. Their flagship technology, TULSA-PRO, combines MRI guidance and robotically-driven ultrasound for treating prostate diseases, while Sonalleve focuses on non-invasive treatments for uterine fibroids and bone metastases.
YTD Price Performance: -21.96%
Average Trading Volume: 8,876
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$267.9M
For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.
